EP4221692B1 - Essigsäure als verarbeitungshilfsmittel für die sprühtrocknung von grundarzneimitteln - Google Patents

Essigsäure als verarbeitungshilfsmittel für die sprühtrocknung von grundarzneimitteln Download PDF

Info

Publication number
EP4221692B1
EP4221692B1 EP21783007.4A EP21783007A EP4221692B1 EP 4221692 B1 EP4221692 B1 EP 4221692B1 EP 21783007 A EP21783007 A EP 21783007A EP 4221692 B1 EP4221692 B1 EP 4221692B1
Authority
EP
European Patent Office
Prior art keywords
solvent
acetic acid
active agent
spray
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP21783007.4A
Other languages
English (en)
French (fr)
Other versions
EP4221692A1 (de
EP4221692C0 (de
Inventor
Michael MORGEN
Warren Miller
David VODAK
Jonathan Cape
Molly ADAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Bend Inc
Original Assignee
Lonza Bend Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Bend Inc filed Critical Lonza Bend Inc
Publication of EP4221692A1 publication Critical patent/EP4221692A1/de
Application granted granted Critical
Publication of EP4221692B1 publication Critical patent/EP4221692B1/de
Publication of EP4221692C0 publication Critical patent/EP4221692C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Definitions

  • the invention discloses a method for preparation of spray dried solid dispersions, SDD, comprising an active agent, AA, such as an active pharmaceutical ingredient, API, and a dispersion polymer, DISPPOL, wherein the spray drying is done with a solution of AA and of DISPPOL in a solvent comprising C 1-3 alkanol and acetic acid, and optionally water.
  • Spray dried solid dispersions comprising an active pharmaceutical ingredient, API, and a dispersion polymer, DISPPOL
  • a volatile solvent such as methanol or acetone
  • spray drying an API suspension can be heated to a temperature either below or above the solvent's ambient pressure boiling point, this is known as "hot spray drying process", resulting in a higher dissolved concentration of API.
  • non-preferred volatile solvents can provide increased solubility of the API, but these solvents have other disadvantages that make them less desirable, e.g. high cost, toxicity, poor equipment compatibility, poor commercial availability, high disposal costs, challenges removing to sufficiently low levels, higher viscosity.
  • WO 2019/220282 A1 discloses in Example 1 spray drying of a solution of erlotinib and a dispersion polymer (PMMAMA or hydroxypropyl methylcellulose acetate succinate H grade) in methanol to provide a spray dried dispersion. The presence of an acid in the spray solution is not mentioned.
  • PMMAMA dispersion polymer
  • hydroxypropyl methylcellulose acetate succinate H grade dispersion polymer
  • WO 2007/060384 A2 discloses in example 4 spray-drying of salbutamol sulphate.
  • example 11 discloses spray-drying of salbutamol sulphate, so again the sulphate is contained in the SDD, not its free base form.
  • 1 ml + ca. 49 ml 50 ml water and ca. 21 ml, that are ca. 17 g of EtOH, assuming the described dilution to 100 ml with aqueous ethanol (30% v/v) needed ca. 70 ml of the aqueous ethanol. So the respective total content of water in the w/o/w emulsion was ca. 75 wt% water based on the combined amount of water and ethanol.
  • CN110037990A discloses solid amorphous dispersions of apixaban.
  • Apixaban has two pKa values, one acidic pKa of ca. 13 at which half of the acidic site is deprotonated, and a basic pKa of ⁇ 2 at which half of the respective basic site is protonated (source: https://go.drugbank.com/drugs/DB06605).
  • a combination of THF and acetic acid is used as solvent, ethanol is mentioned only for providing low solubility for apixaban.
  • WO 2015/138837 A1 discloses amorphous solid dispersions of ivosidenib.
  • Ivosidenib has a basic pKa of ca. 1.81 (https://go.drugbank.com/drugs/DB14568). Only one example of spray drying is disclosed, no acid was contained in the spray mixture.
  • US 2007/0218012 A1 discloses in the examples methylene chloride and acetone as spray solvents for preparing sold dispersion of VX-950, Telaprevir, which has a basic pKa of -0.69 (https://go.drugbank.com/drugs/DB05521).
  • WO 2013/105894 A1 discloses the preparation of stable, amorphous hybrid nanoparticles with various protein kinase inhibitors PKI.
  • Solvents used are DMSO, acetone and trifluoroethanol (TFE).
  • TFE trifluoroethanol
  • a solution of PKI and polymer in said solvents is pumped through XSpray's RightSize nozzle together with a CO 2 stream, which method is different from conventional spray drying of a spray solution. Neither C 1-3 alkanols nor acetic acids are mentioned.
  • acetic acid may be used as processing aid in such spray drying method.
  • the solubility of the AA is increased, which allows for higher concentration of AA in the spray solution than in absence of acetic acid.
  • Increased AA solubility gives higher manufacturing throughput, and potentially better spray dried particle characteristics than what is achievable with lower solids content spray solutions.
  • acetic acid is used not only as a processing aid, but as the only solvent then viscosities tend to be high.
  • Subject of the invention is a method SPRAYDRY for preparing a spray dried solid dispersion, SDD, of an active agent, AA, which is an organic Bronstedt base, comprising:
  • Figure 1 PXRD patterns for Examples 6 to 9 showing the amorphous nature of the samples.
  • SDD is a spray dried solid dispersion of AA in DISPPOL.
  • AA and DISPPOL are preferably homogeneously mixed in SDD.
  • AA may be homogeneously and preferably also molecularly dispersed in DISPPOL.
  • AA and DISPPOL may form a solid solution in SDD.
  • AA may be amorphous or substantially amorphous in SDD; substantially means that at least 80 wt%, preferably at least 90 wt%, more preferably at least 95 wt%, even more preferably at least 98 wt%, especially at least 99% wt%, of AA is amorphous; the wt% being based on the total weight of AA in SDD.
  • SDD therefore may be an amorphous SDD.
  • the amorphous nature of AA may be evidenced by a lack of sharp Bragg diffraction peaks in the x-ray pattern when SDD is analyzed by a powder X-Ray Diffraction, PXRD.
  • Possible parameters and settings for a x-ray diffractometer are equipment with a Cu-Kalpha source, setting in modified parallel beam geometry between 3 and 40° 2Theta and a scan rate of 2°/min with a 0.0° step size.
  • Another evidence for the amorphous nature of AA in the SDD may be a single glass transition temperature, Tg.
  • a single Tg is also evidence of a homogeneous mixture of amorphous AA and polymer.
  • Samples as such without any further sample preparation may be used for the determination of the Tg, the determination may run for example in modulated mode at a scan rate of 2.5 °C/min, modulation of ⁇ 1.5 °C/min, and a scan range from 0 to 180 °C.
  • Amorphous nature of AA shows a Tg which is equal to the Tg of neat DSISPPOL or which is between the Tg of the polymer and the Tg of the AA.
  • the Tg of the SDD is often similar to the weighted average of the Tg of AA and the Tg of DISPPOL.
  • SDD is amorphous or substantially, SDD can also be called ASD.
  • SPRAYSOL is a stable solution of AA in SOLV and acetic acid.
  • SPRAYSOL has only one liquid phase. This means that the liquid phase of SPRAYSOL has not more than one liquid phase but is has only one liquid phase, so for example it has not 2 or 3 separate liquid phases, which would be the case if a liquid phase would be a water/oil or water/oil/water emulsion or the like.
  • the amount of AA with respect to SOLV is above the solubility of AA in SOLV in absence of acetic acid.
  • Possible amount of AA in SPRAYSOL may be at least 0.5 wt%, preferably at least 1 wt%, more preferably at least 3 wt%, with the wt% being based on the weight of SPRAYSOL.
  • Possible amount of AA may be up to 10 wt%, preferably up to 7.5 wt%, more preferably up to 5 wt%.
  • possible amounts of AA in SPRAYSOL may be from 0.5 wt% to 10 wt%, preferably from 1 wt% to 10 wt%, more preferably from 3 wt% to 10 wt%, with the wt% being based on the weight of SPRAYSOL.
  • the amount of acetic acid is sufficient to solubilize AA in SOLV.
  • the amount of acetic acid may be 1 to 50 eq, preferably 1 to 40 eq, more preferably 1 to 30 eq, even more preferably 1 to 25 eq, based on the molar amount of AA.
  • the amount of acetic acid may be up to 50 wt%, preferably up to 40 wt%, more preferably up to 30 wt%, even more preferably up to 25 wt%, especially up to 15 wt%, more especially up to 10 wt%, even more especially up to 7.5, in particular up to 5 wt%, the wt% being based on the weight of SOLV.
  • the amount of acetic acid may be from 0.05 to 50 wt%, preferably from 0.05 to 40 wt%, more preferably from 0.05 to 30 wt%, even more preferably from 0.05 to 25 wt%, especially from 0.05 to 15 wt%, more especially from 0.1 to 10 wt%, even more especially from 0.1 to 7.5, in particular from 0.1 to 5 wt%, the wt% being based on the weight of SOLV.
  • the C 1-3 alkanol of SOLV may be methanol, ethanol or isopropanol, preferably methanol or ethanol, more preferably methanol.
  • the amount of the C 1-3 alkanol in SOLV may be at least 60 wt%, or at least 65 wt%, or at least 67.5 wt%, or at least 70 wt%, or at least 75 wt%, or at least 80 wt%, or at least 85 wt%, or at least 90 wt%, or at least 95 wt%; with the wt% being based on the weight of SOLV.
  • SOLV may further comprise water.
  • SOLV comprises water
  • SOLV comprises not more than 40 wt%, preferably not more than 35 wt%, more preferably not more than 32.5 wt%, even more preferably not more than 30 wt%, especially not more than 25 wt%, more especially not more than 20 wt%, of water, with the wt% being based on the combined weights of C 1-3 alkanol and water.
  • the weight ratio C 1-3 alkanol : water in SOLV may be from 99 : 1 to 60 : 40, preferably from 99 : 1 to 65 : 35, more preferably from 99 : 1 to 67.5 : 32.5, even more preferably from 99 : 1 to 70 : 30, especially from 99 : 1 to 75 : 25, more especially from 99 : 1 to 80 : 20.
  • SOLV consists of C 1-3 alkanol and water.
  • SOLV consists of C 1-3 alkanol.
  • AA is in its free base form when combined with or added to the acetic acid and SOLV to form SPRAYSOL.
  • AA may be present in SPRAYSOL in its free base form, in its protonated form or in both forms, depending on its basic pKa.
  • the SDD may comprise from 1 to 99 wt%, preferably from 10 to 95 wt%, more preferably from 10 to 80 wt%, even more preferably from 20 to 60 wt%, of AA, the wt% being based on the weight of the SDD.
  • the SDD may comprise from 1 to 99 wt%, preferably from 20 to 90 wt%, more preferably from 40 to 80 wt%, of DISPPOL, the wt% being based on the weight of the SDD.
  • the combined content of AA and DISPPOL in SDD is from 65 to 100 wt%, more preferably from 67.5 to 100 wt%, even more preferably from 80 to 100 wt%; especially from 90 to 100 wt%; more especially from 95 to 100 wt%;
  • Relative amounts of AA to DISPPOL in SDD may be from 50 : 1 to 1 : 50, preferably from 25 : 1 to 1 : 25, more preferably from 10 : 1 to 1 : 10 (w/w).
  • Amounts of DISPPOL and of AA in SPRAYSOL are chosen such that a predefined amount of DISPPOL and of AA in SDD provided.
  • DISPPOL is present in SPRAYSOL in a dissolved state, the amounts of DISPPOL and SOLV are chosen respectively.
  • amounts of DISPPOL in SPRAYSOL may be from 0.5 wt% to 20 wt%, preferably from 1 wt% to 20 wt%, more preferably from 2.5 wt% to 15 wt%, even more preferably from 5 wt% to 10 wt%, with the wt% being based on the weight of SPRAYSOL.
  • AA may have a solubility of 30 mg/mL or less, more preferably of 20 mg/mL or less, even more preferably of 10 mg/mL or less, in SOLV.
  • AA is an organic Bronstedt base.
  • AA may be a biologically active compound.
  • the biologically active compound may be desired to be administered to a patient in need of AA.
  • AA may be a drug, medicament, pharmaceutical, therapeutic agent, nutraceutical, an active pharmaceutical ingredient, API.
  • AA may be a "small molecule,” generally having a molecular weight of 2000 Daltons or less.
  • An API, that is AA, may be dasatinib or gefitinib.
  • SPRAYDRY recovers and provides AA in its free base form, so essentially all of AA is present in the SDD in its free base form, this means that the basic site of AA which has said basic pKa of 4 or greater is essentially present in deprotonated state in the SDD.
  • AA has a basic pKa of 5 or greater.
  • DISPPOL may comprise one or more dispersion polymers, preferably 1, 2, 3 or 4, more preferably 1, 2 or 3, even more preferably 1 or 2 dispersion polymers.
  • DISPPOL may be a pharmaceutically acceptable dispersion polymer.
  • Suitable DISPPOL include, but are not limited to, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), cellulose acetate phthalate (CAP), carboxymethyl ethyl cellulose (CMEC), polyvinylpyrrolidone (PVP), poly(vinylpyrrolidone-co-vinyl acetate) (PVP-VA), poly(methacrylic acid-co-methyl methacrylate) (PMMAMAA), poly(methacrylic acid-co-ethyl acrylate), or any combination thereof.
  • HPMCAS hydroxypropyl methylcellulose acetate succinate
  • HPMCP hydroxypropyl methylcellulose phthalate
  • HPMC hydroxypropyl methyl cellulose
  • HPMC hydroxypropyl cellulose
  • HPMC hydroxypropyl cellulose
  • HPMC
  • Suitable PMMAMAA polymers include, but are not limited to, poly(methacrylic acid-co-methyl methacrylate) 1:1 (for example Eudragit ® L100), and poly(methacrylic acid-co-methyl methacrylate) 1:2 (for example Eudragit ® S100).
  • Eudragit ® are polymer products of Evonik Industries AG, 45128 Essen, Germany.
  • the poly(methacrylic acid-co-ethyl acrylate) may be poly(methacrylic acid-co-ethyl acrylate) 1:1.
  • DISPPOL is HPMCAS or PMMAMAA.
  • SPRAYSOL may be fed into the spray dryer with a temperature of SPRAYSOL up to the boiling point of SPRAYSOL at ambient pressure; preferably with a temperature of from 4 °C to the boiling point of SPRAYSOL at ambient pressure, preferably from 4 °C to a temperature below the boiling point of SPRAYSOL at ambient pressure, more preferably from room temperature to 60°C.
  • the term "SPRAYSOL may be fed into the spray dryer with a temperature of SPRAYSOL” means that "SPRAYSOL is spray dried with a temperature of SPRAYSOL".
  • the spray drying may be done with an inlet temperature of from 60 to 165 °C.
  • the spray drying may be done with an outlet temperature equal to or less than the boiling point of SOLV.
  • the spray drying may be done with any inert gas commonly used for spray drying, such as nitrogen.
  • the spray drying does preferably not use CO 2 for dissolving or solubilizing AA.
  • CO 2 is preferably not added to or mixed with SPRAYSOL.
  • CO 2 is preferably not mixed with SPRAYSOL in the nozzle of the spray dryer.
  • SPRAYSOL may further comprises a dissolved surfactant SURF.
  • SURF may be mixed with SPRAYSOL.
  • SURF may be for example a fatty acid and alkyl sulfonate, docusate sodium (for example available from Mallinckrodt Spec. Chem., St. Louis, Mo.), polyoxyethylene sorbitan fatty acid esters (for example Tween ® , available from ICI Americas Inc, Wilmington, Del., or Liposorb ® P-20, available from Lipochem Inc, Patterson, N.J., or Capmul ® POE-0, available from Abitec Corp., Janesville, Wis.), natural surfactants such as sodium taurocholic acid, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, lecithin, other phospholipids and mono- and diglycerides, vitamin E TPGS, PEO-PPO-PEO triblock copolymers (for example known under the tradename pluronics), or PEO (PEO are also called PEG, polyethyleneglycols (PEG)).
  • the amount of SURF may be up to 10 wt%, the wt% being based on the weight of SDD.
  • SPRAYSOL may further comprises pharmaceutically acceptable excipients, such as fillers, disintegrating agents, pigments, binders, lubricants, flavorants, and so forth which can be used for customary purposes and in typical amounts known to the person skilled on the art.
  • pharmaceutically acceptable excipients such as fillers, disintegrating agents, pigments, binders, lubricants, flavorants, and so forth which can be used for customary purposes and in typical amounts known to the person skilled on the art.
  • the SDD may comprise residual acetic acid, preferably in low amounts; the content of residual acetic acid in SDD may be 5'000 ppm or less, preferably 500 ppm or less, more preferably of 100 ppm or less, the ppm being based on the weight of SDD.
  • any content of residual acetic acid in SDD may be lowered to a predefined content of residual acetic acid, this may be done with an additional drying step after spray drying.
  • the SDD may comprise residual SOLV, the content of residual SOLV in SDD may be 5'000 ppm or less, preferably 3'000 ppm or less, more preferably 500 ppm or less, even more preferably of 100 ppm or less, the ppm being based on the weight of SDD.
  • any content of residual SOLV in SDD may be lowered to a predefined content of residual SOLV in SD.
  • Any residual content of acetic acid or of SOLV in SDD may be reduced to the desired predefined and final content by submitting SDD after the spray drying to a second drying.
  • Secondary drying may be done using a tray dryer or any agitated dryer known to the skilled person for drying solids.
  • SDD spray dried solid dispersion
  • Example 1 Solubility of dasatinib in methanol
  • Dasatinib free base was recrystallized from methanol and dried. Crystalline dasatinib was added in excess to methanol to form a saturated solution at 25 °C. The solution was analyzed by TGA and found to contain 3.1 mg/mL dasatinib.
  • Example 2 Increasing dasatinib concentration dissolved in methanol with acetic aid
  • HPMCAS-MG polymer 7.51 g, was dissolved in 98.2 g of methanol at 19 °C.
  • Crystalline dasatinib free base 2.50 g was added forming a slurry.
  • Glacial acetic acid 6.5 g (21 eq based on the molar amount of dasatinib), was added with stirring and placed in a 25 °C water bath for 1 hour converting the slurry into a solution with 8.7 wt% dissolved solids. The solution was removed from the water bath, allowed to cool for 30 min to 19 °C and then spray-dried.
  • the solution did not contain dasatinib in solid form, instead it contained the dasatinib in a completely dissolved state, and it had only one liquid phase.
  • the solution was spray dried using a custom built lab-scale spray dryer.
  • the solution was pumped into a lab-scale 0.3 m diameter stainless steel spray drying chamber using a peristaltic pump.
  • the flow rate of the solution was 20 g/min.
  • atomization was done through a two-fluid nozzle 1 ⁇ 4 J series with an 1650 liquid body and 64 air cap made by Spraying Systems Company, Glendale Heights, II, 60187-7901, US.
  • Sheath gas was used to atomize the solution at a pressure of 15 psi.
  • Heated nitrogen gas was introduced into the spray chamber at a temperature of 115 to 120 °C and flow rate of 500 g/min.
  • the outlet temperature of the gas exiting the chamber was 45 to 50 °C.
  • the resulting SDD was collected using a cyclone to separate the solid particles from the gas stream.
  • Residual acetic acid was removed by drying on a tray dryer at 60 °C and 30% RH for 8 h.
  • the residual acetic acid was measured to be 230 ppm by GC.
  • the residual methanol was measured to be below 100 ppm by GC.
  • PXRD shows a homogeneous amorphous solid dispersion.
  • Eudragit L-100 (PMMAMAA) polymer 7.50 g, was dissolved in 98.4 g of methanol at 19 °C.
  • Crystalline dasatinib free base 2.51 g, was added forming a slurry.
  • Glacial acetic acid 6.5 g (21 eq based on the molar amount of dasatinib), was added with stirring and placed in a 25 °C water bath for 30 min converting the slurry into a solution with 8.7 wt% dissolved solids. The solution was removed from the water bath, allowed to cool for 30 min to 19 °C and then spray-dried.
  • the solution did not contain dasatinib in solid form, instead it contained the dasatinib in a completely dissolved state, and it had only one liquid phase.
  • the solution was spray dried using a custom built lab-scale spray dryer.
  • the solution was pumped into a lab-scale 0.3 m diameter stainless steel spray drying chamber using a peristaltic pump.
  • the flow rate of the solution was 20 g/min.
  • atomization was done through a two-fluid nozzle 1 ⁇ 4 J series with an 1650 liquid body and 64 air cap made by Spraying Systems Company, Glendale Heights, IL 60187-7901, United States.
  • Sheath gas was used to atomize the solution at a pressure of 15 psi.
  • Heated nitrogen gas was introduced into the spray chamber at a temperature of 115 to 120 °C and flow rate of 500 g/min.
  • the outlet temperature of the gas exiting the chamber was 45 to 50 °C.
  • the resulting SDD was collected using a cyclone to separate the solid particles from the gas stream.
  • Residual acetic acid was removed by drying on a tray dryer at 60 °C and 30% RH for 24 h.
  • the residual acetic acid was measured to be 5'000 ppm by GC.
  • the residual methanol was measured to be below 100 ppm by GC.
  • PXRD shows a homogeneous amorphous solid dispersion.
  • the solubility of gefitinib in solvent mixtures with acetic acid were obtained by suspending 300 mg of crystalline gefitinib in 5 mL of solvent (methanol:water) containing 150 microliters of acetic acid at 20 °C (3.9 eq of acetic acid). With the exception of 100% methanol, all solutions were visually soluble at 60 mg/mL.
  • the solubility in 100% methanol with acetic acid was determined after separating undissolved solids by centrifugation of a 1 mL aliquot at 10'000 RCF for 3 min after 1 hour of stirring. The supernatant was then analyzed for gefitinib concentration by HPLC.
  • Table 1 shows the gefitinib solubility enhancement in solvent mixtures using 3.9 eq of acetic acid; the enhancement is expressed in Table 1 in form of an Enhancement Factor which is the ratio of Solubility with acetic acid / Solubility without acetic acid
  • Table 1 Solvent composition Methanol:H 2 O Solubility without acetic acid [mg/mL] Solubility with acetic acid (*) [mg/mL] Enhancement factor 100:0 5.2 31 5.9 90:10 6.0 >60 >10 80:20 6.3 >60 >10 70:30 4.0 >60 >15 60:40 2.1 >60 >29 (*) 3.9 molar equivalents of acetic acid added
  • Table 2 shows the spray solution compositions for examples 6 to 9 Table 2
  • a slurry was made by first dissolving 9 g of HPMCAS-MG in a mixture of 98 g of methanol and 18.7 g water at 22 °C, and then adding 3 g of crystalline gefitinib to form a drug slurry. To this slurry was added 11 mL of 0.075 g/mL glacial acetic acid in methanol. The mixture was stirred for at least 30 min to dissolve the drug and thereby to form a solution SPRAYSOLV.
  • SPRAYSOLV did not contain gefitinib in solid form, instead it contained the gefitinib in a completely dissolved state, and it had only one liquid phase.
  • the solution was spray dried using a custom built spray dryer.
  • the solution was pumped into a lab-scale 0.3 m diameter stainless steel spray drying chamber using a peristaltic pump at a solution flow rate of 15 g/min.
  • the spray solution was atomized using a two-fluid 1 ⁇ 4 J series nozzle with a 1650 liquid body and 64 air cap (Spraying Systems Company, Glendale Heights, IL 60187-7901, US).
  • Room temperature sheath gas (15 to 20 psi) was used to atomize the solution and heated nitrogen gas (115 to 125 °C inlet, 45 to 50 °C outlet, 500 g/min) was used to dry the particles.
  • the resulting SDD was collected using a cyclone to separate the solid particles from the gas stream.
  • a slurry was made by first dissolving 9 g of HPMCAS-MG in a mixture of 83.1 g of methanol and 39.1 g water at 22 °C, and then adding 3 g of crystalline gefitinib to form a drug slurry. To this slurry was added 11 mL of 0.075 g/mL glacial acetic acid in methanol. The mixture was stirred for at least 30 minutes to dissolve the drug. The mixture was stirred for at least 30 min to dissolve the drug and thereby to form a solution SPRAYSOLV. SPRAYSOLV did not contain gefitinib in solid form, instead it contained the gefitinib in a completely dissolved state, and it had only one liquid phase.
  • a slurry was made by first dissolving 9 g of HPMC E3 in a mixture of 51.1 g of methanol and 25.3 g water at 22 °C, adding an additional 42.3 g methanol after the HPMC E3 was dissolved, then adding 3 g of crystalline gefitinib. To this slurry was added 10 mL of 0.075 g/mL glacial acetic acid in methanol. The mixture was stirred for at least 30 min to dissolve the drug and thereby to form a solution SPRAYSOLV.
  • SPRAYSOLV did not contain gefitinib in solid form, instead it contained the gefitinib in a completely dissolved state, and it had only one liquid phase.
  • a slurry was made by first dissolving 9 g of PVP-VA64 in a mixture of 98 g of methanol and 18.6 g water at 22 °C, and then adding 3 g of crystalline gefitinib to form a drug slurry. To this slurry was added 11 mL of 0.075 g/mL glacial acetic acid in methanol. The mixture was stirred for at least 30 min to dissolve the drug and thereby to form a solution SPRAYSOLV. SPRAYSOLV did not contain gefitinib in solid form, instead it contained the gefitinib in a completely dissolved state, and it had only one liquid phase.
  • Figure 1 shows the PXRD patterns for Examples 6 to 9, tray dried for 24 h at 40 °C / 15% RH. The lack of sharp diffraction peaks suggests the drug is amorphous. SDDs dried at 60 °C / 30% RH showed similar PXRD patterns.

Claims (23)

  1. Verfahren zum Herstellen einer sprühgetrockneten Feststoffdispersion eines Wirkstoffs, bei dem es sich um eine organische Bronstedt-Base handelt, umfassend:
    a. Kombinieren eines Wirkstoffs, eines Dispersionspolymers, Essigsäure und eines Lösungsmittels, um eine Sprühlösung zu bilden, wobei
    i. das Lösungsmittel ein C1-3-Alkanol umfasst,
    die Menge an C1-3-Alkanol in dem Lösungsmittel mindestens 50 Gew.-% beträgt, wobei die Gew.-% auf das Gewicht des Lösungsmittels bezogen sind;
    ii. der Wirkstoff in Form seiner freien Base vorliegt, wenn er mit der Essigsäure und dem Lösungsmittel zum Bilden der Sprühlösung kombiniert wird, und in Form seiner freien Base einen basischen pKa-Wert von 4 oder höher aufweist und der Wirkstoff eine Löslichkeit von 40 mg/ml oder weniger in dem Lösungsmittel aufweist,
    iii. die Sprühlösung keine übersättigte Lösung des Wirkstoffs in dem Lösungsmittel und der Essigsäure ist;
    b. Sprühtrocknen der Sprühlösung, um eine sprühgetrocknete Feststoffdispersion zu bilden, die den Wirkstoff und das Dispersionspolymer umfasst;
    wobei die Sprühlösung nur eine flüssige Phase aufweist.
  2. Verfahren nach Anspruch 1, wobei
    die Menge an Wirkstoff in Bezug auf das Lösungsmittel ohne Essigsäure über der Löslichkeit des Wirkstoffs in dem Lösungsmittel liegt.
  3. Verfahren nach Anspruch 1 oder 2, wobei
    die Menge an Wirkstoff in der Sprühlösung mindestens 0,5 Gew.-% beträgt, wobei die Gew.-% auf das Gewicht der Sprühlösung bezogen sind.
  4. Verfahren nach einem oder mehreren der Ansprüche 1 bis 3, wobei
    die Menge an Essigsäure 1 bis 50 Äq. beträgt, bezogen auf die molare Menge an Wirkstoff.
  5. Verfahren nach einem oder mehreren der Ansprüche 1 bis 3, wobei
    die Menge an Essigsäure 0,05 bis 50 Gew.-% beträgt, wobei die Gew.-% auf das Gewicht des Lösungsmittels bezogen sind.
  6. Verfahren nach einem oder mehreren der Ansprüche 1 bis 5, wobei
    das Lösungsmittel Methanol, Ethanol oder Isopropanol ist.
  7. Verfahren nach einem oder mehreren der Ansprüche 1 bis 6, wobei
    das Lösungsmittel ferner Wasser umfasst.
  8. Verfahren nach Anspruch 7, wobei
    das Gewichtsverhältnis C1-3-Alkanol : Wasser in dem Lösungsmittel 99 : 1 bis 60 : 40 betragen kann.
  9. Verfahren nach einem oder mehreren der Ansprüche 1 bis 8, wobei
    die sprühgetrocknete Feststoffdispersion 1 bis 99 Gew.-% Wirkstoff umfasst, wobei die Gew.-% auf das Gewicht der sprühgetrockneten Feststoffdispersion bezogen sind.
  10. Verfahren nach einem oder mehreren der Ansprüche 1 bis 9, wobei
    die sprühgetrocknete Feststoffdispersion 1 bis 99 Gew.-% des Dispersionspolymers umfasst, wobei die Gew.-% auf das Gewicht der sprühgetrockneten Feststoffdispersion bezogen sind.
  11. Verfahren nach einem oder mehreren der Ansprüche 1 bis 10, wobei
    der kombinierte Gehalt an Wirkstoff und Dispersionspolymer in der sprühgetrockneten Feststoffdispersion 65 bis 100 Gew.-% beträgt, wobei die Gew.-% auf das Gewicht der sprühgetrockneten Feststoffdispersion bezogen sind.
  12. Verfahren nach einem oder mehreren der Ansprüche 1 bis 11, wobei der Wirkstoff eine biologisch aktive Verbindung ist.
  13. Verfahren nach einem oder mehreren der Ansprüche 1 bis 12, wobei
    der Wirkstoff ein Arzneistoff, ein Medikament, ein Pharmazeutikum, ein Therapeutikum, ein Nutrazeutikum, ein pharmazeutischer Wirkstoff ist.
  14. Verfahren nach einem oder mehreren der Ansprüche 1 bis 13, wobei
    der Wirkstoff einen basischen pKa von 5 oder höher aufweist.
  15. Verfahren nach einem oder mehreren der Ansprüche 1 bis 14, wobei
    das Dispersionspolymer ein oder mehrere Dispersionspolymere umfasst.
  16. Verfahren nach einem oder mehreren der Ansprüche 1 bis 15, wobei
    das Dispersionspolymer ein pharmazeutisch verträgliches Dispersionspolymer ist.
  17. Verfahren nach einem oder mehreren der Ansprüche 1 bis 16, wobei
    das Dispersionspolymer Hydroxypropylmethylcelluloseacetatsuccinat, Hydroxypropylmethylcellulosephthalat, Hydroxypropylmethylcellulose, Hydroxypropylcellulose, Celluloseacetatphthalat, Carboxymethylethylcellulose, Polyvinylpyrrolidon, Poly(vinylpyrrolidon-co-vinylacetat), Poly(methacrylsäure-co-methylmethacrylat), Poly(methacrylsäure-co-ethylacrylat) oder eine beliebige Kombination davon ist.
  18. Verfahren nach einem oder mehreren der Ansprüche 1 bis 17, wobei
    das Dispersionspolymer HPMCAS oder PMMAMAA ist.
  19. Verfahren nach einem oder mehreren der Ansprüche 1 bis 18, wobei
    die SDD restliche Essigsäure umfasst; der Gehalt an restlicher Essigsäure in der sprühgetrockneten Feststoffdispersion 5.000 ppm oder weniger beträgt, wobei die ppm auf das Gewicht der sprühgetrockneten Feststoffdispersion bezogen sind.
  20. Verfahren nach einem oder mehreren der Ansprüche 1 bis 19, wobei
    die SDD Restlösungsmittel umfasst, der Gehalt an Restlösungsmittel in der sprühgetrockneten Feststoffdispersion 5.000 ppm oder weniger beträgt, wobei die ppm auf das Gewicht der sprühgetrockneten Feststoffdispersion bezogen sind.
  21. Verfahren nach einem oder mehreren der Ansprüche 1 bis 6 und 9 bis 20, wobei
    das Lösungsmittel aus C1-3-Alkanol besteht.
  22. Verfahren nach einem oder mehreren der Ansprüche 1 bis 21, wobei
    das Lösungsmittel aus C1-3-Alkanol und Wasser besteht.
  23. Sprühgetrocknete Feststoffdispersion, erhältlich durch das Verfahren nach einem der Ansprüche 1 bis 22.
EP21783007.4A 2020-10-02 2021-09-30 Essigsäure als verarbeitungshilfsmittel für die sprühtrocknung von grundarzneimitteln Active EP4221692B1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063086691P 2020-10-02 2020-10-02
EP20200895 2020-10-08
EP20208785 2020-11-20
EP21150829 2021-01-11
EP21177685 2021-06-04
PCT/EP2021/076996 WO2022069661A1 (en) 2020-10-02 2021-09-30 Acetic acid as processing aid in spray drying for basic drugs

Publications (3)

Publication Number Publication Date
EP4221692A1 EP4221692A1 (de) 2023-08-09
EP4221692B1 true EP4221692B1 (de) 2023-12-20
EP4221692C0 EP4221692C0 (de) 2023-12-20

Family

ID=78000724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21783007.4A Active EP4221692B1 (de) 2020-10-02 2021-09-30 Essigsäure als verarbeitungshilfsmittel für die sprühtrocknung von grundarzneimitteln

Country Status (6)

Country Link
US (1) US20230414515A1 (de)
EP (1) EP4221692B1 (de)
JP (1) JP2023544998A (de)
CN (1) CN116234537A (de)
CA (1) CA3194380A1 (de)
WO (1) WO2022069661A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0524194D0 (en) 2005-11-28 2006-01-04 Univ Aston Respirable powders
EA018811B1 (ru) 2006-03-20 2013-10-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
EP3181128B1 (de) 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmazeutische zusammensetzung
PL3116491T3 (pl) 2014-03-14 2022-02-07 Les Laboratoires Servier Kompozycje farmaceutyczne związków terapeutycznie aktywnych
WO2019220282A1 (en) 2018-05-14 2019-11-21 Capsugel Belgium Nv Solid dosage forms with high active agent loading
CN110037990B (zh) 2019-04-15 2023-03-28 海正药业(杭州)有限公司 一种阿哌沙班固体无定形分散体的制备工艺

Also Published As

Publication number Publication date
JP2023544998A (ja) 2023-10-26
EP4221692A1 (de) 2023-08-09
EP4221692C0 (de) 2023-12-20
CA3194380A1 (en) 2022-04-07
CN116234537A (zh) 2023-06-06
WO2022069661A1 (en) 2022-04-07
US20230414515A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
CA2317106C (en) Method and composition of an oral preparation of itraconazole
RU2240827C2 (ru) Фармацевтическая композиция, способы ее приготовления, стабильные водонерастворимые комплексы, способ превращения терапевтически активного соединения и терапевтически активное соединение
JP5439182B2 (ja) 化学物質のミセルのナノ粒子
US7923026B2 (en) Embedded micellar nanoparticles
US10322126B2 (en) Solid dispersions of low-water solubility actives
EP1372611B1 (de) Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
Kim et al. Micronization of a poorly water-soluble drug, fenofibrate, via supercritical-fluid-assisted spray-drying
US9737538B2 (en) Solid dispersions of low-water solubility actives
Choi et al. Enhanced oral bioavailability of Rivaroxaban-Loaded microspheres by optimizing the polymer and surfactant based on molecular interaction mechanisms
EP4221692B1 (de) Essigsäure als verarbeitungshilfsmittel für die sprühtrocknung von grundarzneimitteln
JP2000281561A (ja) 新規溶媒法固体分散体製剤
EP4346777A1 (de) Ameisensäure als verarbeitungshilfsmittel bei der sprühtrocknung basischer arzneimittel
EP4351523A1 (de) Sprühtrocknung von api in übersättigten lösungen mit ameisensäure
WO2022018220A1 (en) Spray drying of supersaturated solutions of api with acetic acid
EP4351522A1 (de) Lösungsmittelgemische für die sprühtrocknung zur herstellung amorpher feststoffdispersionen
CN117396192A (zh) 在包含甲酸的过饱和溶液中的api的喷雾干燥
CN117396191A (zh) 用于制备无定形固体分散体的喷雾干燥用混合溶剂
Pillai Development and Characterization of Solid Dosage form Incorporating Camptothecin Analog Nanoparticles

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17P Request for examination filed

Effective date: 20230330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17Q First examination report despatched

Effective date: 20230728

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
INTG Intention to grant announced

Effective date: 20231012

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021007935

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20231222

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240321